# US 2006/0153849 A1 · Methods of treatment with an antibody that suppresses growth differentiation factor-14 activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153849 A1
- Document ID: US20060153849A1
- Status: Published application
- Kind: A1
- Application number: 11/353,277
- Filed: 2006-02-13
- Published: 2006-07-13
- Earliest claimed: 1996-03-29
- Assignees: The Johns Hopkins University School of Medicine
- Inventors: Se-Jin Lee; Christopher Rankin
- Web page: https://patentgrep.com/patent/US20060153849A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/495: Transforming growth factor [TGF]
- C07K 14/52: Cytokines; Lymphokines; Interferons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Growth differentiation factor-14 (GDF-14) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-14 polypeptide and polynucleotide sequences.

## Claims

### Claim 1

A method of treating an immunologic disorder associated with expression of GDF-14 in a subject, comprising contacting cells expressing GDF-14 with a reagent that suppresses or enhances GDF-14 expression.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immunologic disorder is associated with abnormal proliferation of lymphocytes.

### Claim 3 (depends on 1)

The method of claim 1, wherein enhancement of GDF-14 suppresses proliferation of B cells and T cells, thereby reducing inflammation in the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the reagent is a GDF-14 antisense sequence.

### Claim 5 (depends on 4)

The method of claim 4, wherein the GDF-14 antisense sequence is introduced into the cell using a recombinant expression vector.

### Claim 6 (depends on 1)

The method of claim 1, wherein the reagent is an anti-GDF-14 antibody or an antigen binding fragment of the antibody, which selectively binds a GDF-14 polypeptide comprising SEQ ID NO: 4.

### Claim 7 (depends on 6)

The method of claim 6, wherein the antibody is a monoclonal antibody.

### Claim 8 (depends on 6)

The method of claim 6, wherein the antibody is a polyclonal antibody.

### Claim 9 (depends on 6)

The method of claim 6, wherein the antigen binding fragment of the antibody comprises an Fab fragment, an FAb′ fragment, an (Fab′)2 fragment or an Fv fragment.

### Claim 10 (depends on 6)

The method of claim 6, wherein the antibody is a single chain antibody.

### Claim 11

A method of treating cancer in a subject, comprising contacting cells expressing GDF-14 with a reagent that suppresses or enhances GDF-14 expression.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer includes gonadal and adrenal tumors.

### Claim 13 (depends on 11)

The method of claim 11, wherein the cancer is colon cancer.

### Claim 14 (depends on 1)

The method of claim 1 1, wherein the reagent is a GDF-14 antisense sequence.

### Claim 15 (depends on 14)

The method of claim 14, wherein the GDF-14 antisense sequence is introduced into the cell using a recombinant expression vector.

### Claim 16 (depends on 11)

The method of claim 11, wherein the reagent is an anti-GDF-14 antibody, or antigen binding fragment of the antibody, which selectively binds a GDF-14 polypeptide comprising SEQ ID NO: 4.

### Claim 17 (depends on 16)

The method of claim 16, wherein the antibody is a monoclonal antibody.

### Claim 18 (depends on 16)

The method of claim 16, wherein the antibody is a polyclonal antibody.

### Claim 19 (depends on 16)

The method of claim 16, wherein the antigen binding fragment of the antibody comprises an Fab fragment, an FAb′ fragment, an (Fab′)2 fragment or an Fv fragment.

### Claim 20 (depends on 16)

The method of claim 16, wherein the antibody is a single chain antibody.
